Mostrar el registro sencillo del ítem
First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort
dc.rights.license | open | en_US |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | GALVIN, Angeline | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | COURTINARD, Coralie | |
dc.contributor.author | BOUTEILLER, Fanny | |
dc.contributor.author | GOURGOU, Sophie | |
dc.contributor.author | DALENC, Florence | |
dc.contributor.author | JACOT, William | |
dc.contributor.author | ARNEDOS, Monica | |
dc.contributor.author | BAILLEUX, Caroline | |
dc.contributor.author | DIERAS, Veronique | |
dc.contributor.author | PETIT, Thierry | |
dc.contributor.author | EMILE, George | |
dc.contributor.author | DUBRAY-LONGERAS, Pascale | |
dc.contributor.author | FRENEL, Jean-Sebastien | |
dc.contributor.author | BACHELOT, Thomas | |
dc.contributor.author | MAILLIEZ, Audrey | |
dc.contributor.author | BRAIN, Etienne | |
dc.contributor.author | DESMOULINS, Isabelle | |
dc.contributor.author | MASSARD, Vincent | |
dc.contributor.author | PATSOURIS, Anne | |
dc.contributor.author | GONCALVES, Anthony | |
dc.contributor.author | GRINDA, Thomas | |
dc.contributor.author | DELALOGE, Suzette | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | BELLERA, Carine | |
dc.date.accessioned | 2024-02-20T08:22:32Z | |
dc.date.available | 2024-02-20T08:22:32Z | |
dc.date.issued | 2024-01-01 | |
dc.identifier.issn | 0959-8049 | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/188248 | |
dc.description.abstractEn | AIM: To describe first-line treatment patterns, overall survival (OS) and real-world progression-free survival (rwPFS) in young women (<40) with metastatic breast cancer (mBC), as compared to women aged 40-69. MATERIALS AND METHODS: Data on adult women diagnosed with mBC (2008-2017) were extracted from the ESME mBC database (NCT03275311) which includes consecutive patients starting first-line metastatic treatment in one of the 18 French Comprehensive cancer centers. We reported first-line therapeutic strategy and prognostic factors of OS and rwPFS for women aged < 40 and 40-69. RESULTS: In total, 14,897 mBC women were included (1512 aged <40). HR+ /HER2- mBC was the most frequent subtype. First-line treatment differed between young patients and older ones for HR+ /HER2- and Triple Negative (TN) mBC. Median OS for women aged < 40 and 40-69, respectively, was 46.9 and 46.2 months for HR+ /HER2- mBC; 13.5 and 15.2 for TN mBC; and, 60.7 and 55.1 for HER2 + mBC. Median rwPFS under first line treatment was 11.6 and 11.9 months for HR+ /HER2- in women aged < 40 and 40-69, respectively; 5.5 and 5.9 for TN, and, 13.3 and 12.9 for HER2 + . Factors associated with shorter OS and rwPFS were similar for both women aged < 40 and 40-69 and included ≥ 3 metastatic sites, visceral metastases, and longer MFI, with time-varying effects observed for several prognostic factors. CONCLUSION: Young women presented more frequently with TN and HER2 + subtypes and aggressive mBC than women aged 40-69 did. Prognostic factors of OS and rwPFS were quite similar between age groups and mBC subtypes. | |
dc.language.iso | EN | en_US |
dc.subject.en | Real-word data | |
dc.subject.en | Metastatic breast cancer | |
dc.subject.en | Survival endpoints | |
dc.title.en | First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort | |
dc.title.alternative | Eur J Cancer | en_US |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1016/j.ejca.2023.113422 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
dc.identifier.pubmed | 37977105 | en_US |
bordeaux.journal | European journal of cancer (Oxford, England . 1990) | en_US |
bordeaux.page | 113422 | en_US |
bordeaux.volume | 196 | en_US |
bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | INSERM | en_US |
bordeaux.team | EPICENE_BPH | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.identifier | hal-04467336 | |
hal.version | 1 | |
hal.date.transferred | 2024-02-20T08:22:35Z | |
hal.popular | non | en_US |
hal.audience | Internationale | en_US |
hal.export | true | |
dc.rights.cc | Pas de Licence CC | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20journal%20of%20cancer%20(Oxford,%20England%20.%201990)&rft.date=2024-01-01&rft.volume=196&rft.spage=113422&rft.epage=113422&rft.eissn=0959-8049&rft.issn=0959-8049&rft.au=GALVIN,%20Angeline&COURTINARD,%20Coralie&BOUTEILLER,%20Fanny&GOURGOU,%20Sophie&DALENC,%20Florence&rft.genre=article |
Archivos en el ítem
Archivos | Tamaño | Formato | Ver |
---|---|---|---|
No hay archivos asociados a este ítem. |